Appointment of Jacques Hendlisz as CATALIS Québec’s New Executive President
CATALIS Quebec is proud to welcome Mr. Jacques Hendlisz to the organization as its new Executive President, effective April 1, 2020. Mr. Hendlisz is widely recognized for his extensive experience in the management of both research and hospital facilities. He served as the Douglas Institute’s Director General from 1994 to 2011 and as Director of Operations of the Goodman Cancer Research Centre from 2011 to 2012. Since 2003, Mr. Hendlisz has served on numerous boards of directors such as those of the McGill Centre for the Convergence of Health and Economics, Research Canada, the Ludmer Foundation, the Graham Boeckh Foundation, and the Fonds de recherche Québec – Santé (FRQS) (from 2004 to 2010). He is currently Chairman of the MNI’s Clinical Research Unit’s Advisory Board.
“I would like to thank the directors of CATALIS Québec for the confidence they have shown in me through this appointment as their organization’s executive presiden,” says Jacques Hendlisz. “CATALIS members and partners can count on my commitment and determination to improving institutional cohesion between research and clinical care so that the two sectors can work together more collaboratively.”
“On behalf of CATALIS Québec’s Board of Directors, and on my personal behalf, I congratulate Mr. Hendlisz on this appointment. His impressive experience will serve as a catalyst for developing new partnerships with major pharmaceutical companies to attract more clinical trials to Quebec,” said Dr. Marc Rivière, Chairman of the Board of Directors of CATALIS Québec. “During the ongoing pandemic, which has highlighted the crucial nature of clinical research, Mr. Hendlisz will focus on the process of restarting clinical trials in the province.”
Mr. Hendlisz will ensure the continuity of the work done by Diane Gosselin, who served as the initiative’s executive chair from its very beginning until last April. “Ms. Gosselin’s contribution to CATALIS Québec’s development and implementation is invaluable,” said Dr. Rivière. “The Board of Directors is grateful for her dedication to the advancement of clinical research in Quebec,” he added.
“I am proud to see how far CATALIS Québec has come. Indeed, significant progress has been made in the field thanks to the collaboration and mobilization of all health network and industry stakeholders in making Québec a world-renowned clinical research hub,” said Ms. Gosselin.
About CATALIS Québec
CATALIS Québec is a non-profit organization dedicated to the advancement and operational excellence of clinical research in Quebec. Our mission is to optimize Quebec’s clinical research environment to maximize private investment and accelerate the development of innovative patient care.
